Quality of Life in Men Treated for Androgenetic Alopecia via a Digital Healthcare Platform: A Retrospective Cohort Study

The researchers reported that a combined oral minoxidil-finasteride regimen significantly improved hair density in men with androgenetic alopecia over 12 months, although further confirmation in different trials is suggested.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

In this study, women with androgenetic alopecia underwent stem cell treatment, which led to significant improvements in sexual arousal and satisfaction, psychological health, and environmental quality of life, but not in physical health or social relationships after six months.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This study reported that over 70% of adults with primary cicatricial alopecia experienced impaired quality of life, primarily influenced by trichodynia and anxiety.

In this study, patients using the digitally enabled platform Keeps for male pattern hair loss treatment reported positive health outcomes, with 81% experiencing hair regrowth or ceasing hair loss after six months.

This study reports no results yet and only indicates an ongoing randomized placebo-controlled trial investigating the effects of microneedling combined with topical dutasteride solution for treating androgenetic alopecia.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This study found that androgenetic alopecia is significantly associated with moderate impairment of health-related quality of life and emotions, but not with depressive symptoms.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.